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PIH20
Small BenefItS Of tHIrd trImeSter CHeCk-UP amOng Pregnant WOmen 
POSItIvely SCreened fOr tHyrOId dISOrderS
Bartakova J1, Jiskra J2
11st Faculty of Medicine Charles University in Prague, Prague 2, Czech Republic, 2General Faculty 
Hospital in Prague, Prague 2, Czech Republic
Objectives: The guidelines of American Thyroid Association (ATA) 2011 recom-
mends in hypothyroid women receiving levothyroxine (LT4) and in untreated 
women with subclinical hypothyroidism and/or positive TPOAb (antibodies 
against thyroid peroxidase) regular laboratory check-up every 4 weeks during the 
1st half of pregnancy and at least once between 26th–32th weeks of gravidity. Our 
aim was to verify whether thyroid check-up between 26th–32thgestation weeks 
is beneficial in terms of LT4 dosage changes. MethOds: We performed a retro-
spective cross-sectional study in 2004–2014 in the Departments of Endocrinology 
of a university hospital and with laboratory assessment in a single center. The 
study included 188 women positively screened for hypothyroidism and/or positive 
TPOAb in first trimester of pregnancy. They were followed and examined according 
to the recommended algorithm by ATA 2011. We assessed serum concentrations 
of TSH, FT4 and TPOAb and evaluated changes of LT4 dosage with regard to week 
of laboratory check-up. Finally, we calculated direct medical costs per LT4 dosage 
change. Results: Of the 188 positively screened women in the first trimester, 104 
(55.3%) were hypothyroid and 84 (44.7%) were euthyroid but TPOAb positive. Overall, 
104 women (55.3%) undergo three laboratory check-ups, 57 (30.3%) four check-ups 
and 27(14.4%) five check-ups. The median entrance dose of LT4 was 50ug/day (range 
0 –170ug/day). The Laboratory check-up between 26th–32th gestation weeks led 
to LT4 dosage change in 18/132 (13.6%) women comparison to 131/167 (35.7%) in 
10th week, 55/142 (38.7%) in 14th week and 43/165 (26.1%) in 20th gestation weeks 
(p< 0.001). Average costs per LT4 dose change per women were 34.71EUR in 10th 
week, 47.01EUR in 14th week, 65.01EUR in 20th week and 127.53EUR in 30thgesta-
tion weeks. cOnclusiOns: Thyroid check-up between 26th–32th gestation weeks 
in women with hypothyroidism and/or positive TPOAb seems to be redundant in 
terms of LT4 dosage changes and produces inadequate high costs.
PIH21
mOdellIng tHe COSt determInantS fOr Older PerSOnS’ tranSItIOnS In 
Care (OPtIC)
Kudinga BM, McCabe C, Cummings G
University of Alberta, Edmonton, AB, Canada
Objectives: The transfers of nursing home (NH) residents to the emergency depart-
ments (ED) is costly for the healthcare systems. In this regard, the cost-analysis 
can be a useful tool to provide evidence-based information to guide resource allo-
cation. In this study, we analyze the cost at different stages of the transitions for 
Edmonton, Alberta, in Canada and evaluate the extent to which nursing home 
attributes, patients’ characteristics, and the transfers’ outcomes are significantly 
associated with the transfers cost. MethOds: We used a representative data col-
lected in 2011 from 398 residents and 28 nursing homes in Edmonton, Alberta from 
multiple levels and sources (facility, residents, healthcare providers, health records, 
administrative databases, etc.). We conducted a preliminary study to describe the 
costs at different stages of the transitions. Statistical modeling was used to identify 
any significant predictors of the transfers cost and estimate the magnitude of their 
impact. We investigated the ordinary least squares (OLS) models, the GLM, and the 
mixed effects regression models for clustered data. Models are assessed based on 
standard goodness-of-fit tests. Results: We find that hospitalization represents 
48% of the transfers total cost, whilst the emergency-department nursing cost 
and the nursing-home cost account for 26% and 10% respectively. The emergency-
Medical-Services account for 10%, and the diagnostic cost represents 3%. The physi-
cians plus consultations and the treatment costs represent 2% each. The estimation 
results show that sociodemographic factors, health characteristics, communication 
of information, healthcare providers’ involvement in the decision, the nature of the 
transfer coordinator, and providing medical care in the nursing home are significant 
predictors of the transfers cost. cOnclusiOns: The results of this analysis may fit 
into a subsequent cost-effectiveness analysis for the transfers cost.
PIH22
COSt-effeCtIveneSS Of CyP2d6 genOtyPIng In Older dePreSSed 
PatIentS, StartIng WItH nOrtrIPtylIne tHeraPy
Berm EJ1, Gout-Zwart JJ1, Luttjeboer J1, Maring JG2, Wilffert B1, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Dicaonessen Hospital Meppel & Bethesda 
Hospital Hoogeveen, Meppel, The Netherlands
Objectives: Genotyping for the cytochrome P450-2D6 has the potency to predict 
differences in metabolism of nortriptyline. This information could optimize treat-
ment. We explored if possible benefits could outweigh genotyping costs for Dutch 
depressed patients in clinical psychiatry. MethOds: First, a decision-tree was 
created to model the first weeks of nortriptyline therapy. In the model, costs of 
hospitalization, therapeutic drug monitoring, and drug costs were captured. Based 
on the patients genetics, patients were distributed among three health states: cor-
rectly, sub-, or supra-therapeutically dosed. Utilities for each of these health states 
and at different points in time were obtained from an expert opinion (nine clini-
cians). Second, an improvement in sub or supra-therapeutically dosed patients to 
correctly dosed patients, was simulated, assuming genotyping would prevent under 
or overdosing. In the base case the improvement was 36%. In addition, we assumed 
genotyping could reduce hospitalization days with a maximum of 3.7 days (aver-
age: 28.6 days). Results from the model without genotyping were compared with 
the genotyping model. In a scenario analyses we varied the effects of genotyping 
to reach cost-effectiveness at € 20 000/quality adjusted life year (QALY) or € 50 000/
QALY. In a univariate sensitivity analysis, effects of lowering genotyping costs were 
examined. A probabilistic sensitivity analysis (PSA) was performed to investigate 
influence of parameter uncertainty. Results: In the base case, the incremental 
cost-effectiveness ratio (ICER) was € 32 697/QALY. For an ICER of € 20 000/QALY, a gen-
otyping facilitated improvement of 45% was needed and for € 50 000/QALY this was 
27%. Lowering the genotype price to € 162 made genotyping cost-saving. Results of 
the PSA indicated a probability of 0.95 for a willingness-to-pay threshold of € 46000/
QALY. cOnclusiOns: Genotyping could be cost-effective and even be cost-saving 
when genotyping costs drops. However, there is a need for more clinical evidence 
to support assumptions made in this model.
PIH23
eCOnOmetrICS analySIS Of nOn-PreSCrIPtIOn medICIneS exPendItUre 
at COmmUnIty PHarmaCIeS In malaySIa
Mohamad Yahaya AH1, Shafie AA2, Hassali MA3
1Hospital Teluk Intan, Teluk Intan, Perak, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 
3Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia
Objectives: The purpose of this study was to develop the econometric model 
predicting the non-prescription medicines expenditure at community pharmacies 
in Malaysia MethOds: This study used data from 2009 Non-Prescription Medicines 
Utilization among Community Pharmacy Patrons in Malaysia (COMPACT1) and Sales 
of Non-Prescription Medicine in Community Pharmacy Malaysia (COMPACT2). The 
prices of non prescription medicines (NPM) in 2009 were updated to prices of 2014, 
based on Malaysian Consumer Price Index. There were four major components in 
the empirical model namely; socio-economic characteristics, health status, utili-
zation behavior and community pharmacy data. The dependent variable was the 
logarithm function of expenditure for purchasing the NPM. Ordinary least square 
method on cross-sectional data was used to predict model of NPM among com-
munity pharmacy patrons. Results: Twenty two percent (22.3%) of variation in 
NPM expenditure was explained by socio-economic characteristics, health status, 
utilization behavior, and community pharmacy data. Age, female, living at urban 
area, and had monthly household income more than RM3000 per month (~USD850) 
were found to have linear positive relationship with money spent. Those custom-
ers who had problem in pain or discomfort had 0.059 units lesser in expenditure of 
NPM. Number of medicines purchased, satisfaction towards price, usage frequency 
of medicines, and the ways of product selection were among variables in utiliza-
tion behavior that had significant linear relationship with NPM. The community 
pharmacy data on the working days and percentage of customers purchasing over 
total customers in a month shows significant negative linear relationship with 
NPM expenditure. cOnclusiOns: The study had given additional insight on the 
economics of self-medication and the role of community pharmacy as supplier 
of health care. The expenditure of NPM in Malaysia can be explained by empirical 
model that includes the purchasers’ socio-economic characteristic, health status, 
NPM utilization behavior and the information regarding utilization of community 
pharmacy.
IndIvIdUal’S HealtH – Patient-reported Outcomes & Patient Preference  
Studies
PIH24
medICatIOn adHerenCe and HealtH exPendItUre COmParISOn Of 
atenOlOl and metOPrOlOl ImmedIate and extended releaSe fOrmS
Adhikari K, Hastings T, Vaidya V
University of Toledo, Toledo, OH, USA
Objectives: The medication adherence of patients using widely prescribed beta 
blockers (Atenolol and Metoprolol) in their extended and immediate release salt 
form remains unidentified. Improving medication adherence has been shown to 
reduce health care costs. Analyzing the treatment having maximum medication 
adherence could reduce overall healthcare costs, offsetting the cost of the medica-
tion itself. The objectives of this study are to 1) compare the medication adherence of 
patients prescribed with Atenolol and Metoprolol in both immediate and extended 
release forms 2) determine the difference in healthcare expenditure between those 
highly adherent to the beta-blockers under study. MethOds: Secondary data analy-
sis using the Medical Expenditure Panel Survey (MEPS) conducted by the Agency 
for Healthcare Research and Quality and the National Center for Health Statistics. 
Medication Possession Ratio (MPR) will be used to calculate the medication adher-
ence. Patients will then be divided into three categories: high adherence (80-100%), 
intermediate adherence (79%-60%), and low adherence (< 60%). Healthcare expendi-
ture will be analyzed for each medication. Healthcare expenditures will then be 
compared between those who are highly adherent to each medication. Healthcare 
costs analyzed will include ER, outpatient, inpatient visits and prescription medica-
tion payments. Results: The patients with Atenolol extended release were asso-
ciated with the lowest adherence. Patients with Metoprolol treatment were more 
adherent than those taking Atenolol (p< 0.0001). Also, within the extended release 
group, Metoprolol Succinate had a greater rate of high adherence than Atenolol 
(p< 0.001). For patients with high medication adherence, the expenditure was the 
lowest for Metoprolol Succinate ($12490.33). Also, for immediate release, Metoprolol 
Tartrate has significantly lower healthcare costs. cOnclusiOns: Metoprolol is 
associated with higher adherence than atenolol. Also, the healthcare expenditure 
for Metoprolol is significantly lower than Atenolol.
PIH25
a SyStematIC revIeW Of tHe USe Of tHe tIme PreferenCe mOdel tO 
exPlOre medICatIOn adHerenCe BeHavIOr
Mezgebe M, Lovett AW
Mercer University, Atlanta, GA, USA
Objectives: Non-adherence to prescription medication has a significant impact 
on a patient’s health; often causing poorer health outcomes, preventable mortality 
and unnecessary utilization of healthcare services. Previous literature has been 
inconsistent as to what factors affect a patients’ adherence to prescription medi-
cation. Time preference, the extent that individuals are willing to discount future 
benefits for immediate benefits, has recently been acknowledged as a framework 
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to understand patient behavior, however, the relationship between time preference 
and medication adherence is not widely understood. This study aims to summarize 
the existing literature on the association between time preference and medication 
adherence. MethOds: A literature search was conducted on Medline, PsycInfo, 
PubMed and CINAHL from January 2000 to 2015 using the keywords “time prefer-
ence”, “patient compliance”, “medication adherence” and “non-adherence”. Studies 
that did not include medication adherence, lacked empirical data on time pref-
erence or assessed time preference with addictive behaviors (e.g. smoking) were 
excluded. A table summarized results, including the publication year, author, study 
design, source and findings. Results: A total of 53 articles were identified and 
nine studies were retained. Only three studies directly investigated the relation-
ship between time preference and medication adherence. Of those, studies in 2001 
examined adherence to hypertension medication in 195 older adults and adherence 
to cholesterol lowering medication in 169 adults. Findings revealed weak to no 
association between time preference and medication adherence. Conversely, a 2013 
study reported time preference as a significant predictor of medication adherence to 
asthma control medications for 47 patients with persistent asthma. cOnclusiOns: 
Taking into account the extent to which patients will worry about adverse future 
outcomes, this review identified very few studies addressing the objective. More 
empirical research must be conducted before any conclusion can be made in 
regard to the impact of a patients’ time preference on their medication adherence 
behaviors.
PIH26
a COmPreHenSIve SUrvey Of managed Care OrganIzatIOn (mCO) 
medICatIOn adHerenCe InterventIOn PrOgramS
Jones C1, Sullivan I1, Bayer JC1, Ng K1, Piracha F1, Boice MH1, Coutts DJ3, Mazlish S2, 
Nagarian A2, Alex SP2, Phani S2, Shah K2, Sheth A2, Sip K2, Van Kempen T2, Basu-Roy UK2
1AllazoHealth, New York, NY, USA, 2The Solution Lab, Inc., New York, NY, USA, 3The Solution Lab, 
New York, NY, USA
Objectives: Medication non-adherence causes hundreds of billions of dollars in 
avoidable costs. This study sought to survey the existing medication adherence 
programs of managed care organizations (MCOs). MethOds: Thirty MCOs were 
interviewed in Spring 2014 about their current and future medication adherence 
programs. 19 small (< 200,000 members) and 11 large (≥ 200,000 members) filled 
out a 19-question (excluding 6 on program characteristics) survey covering the 
strategies and methods used to improve patient adherence. Results: The MCOs 
dedicate the majority of adherence resources toward cardiovascular disease states 
but most are looking to expand to more disease states. Just two (7%) of the MCOs 
surveyed use predictive analytics to target patients for their intervention programs 
while 12 (40%) use retrospective adherence measures. 75% of MCOs are looking 
to expand their adherence programs while 60% specifically plan to use predictive 
analytics in the future. Only two (7%) only used outsourced interventions, 10 (33%) 
used in-house and 18 (60%) used some combination of the two. 20 (67%) MCOs 
used live call interventions and only 2 (7%) used text reminders. 14 small (74%) 
and 9 (82%) large MCOs used direct mail interventions. 20 (67%) of the MCOs rated 
their intervention programs to be “moderately effective.” cOnclusiOns: Most 
MCOs prioritize adherence to cardiovascular disease medication but most are 
also interested in expanding their programs. Few MCOs use enhanced platforms 
to select patients for interventions but many plan on expanding their platforms. 
MCOs intervened to improve adherence largely through provider-centric chan-
nels and with a combination of in-house and outsourced methods. Many MCOs 
are interested in adopting a platform that identifies high-value interventions, 
like AllazoHealth, since current programs aren’t personalized and are perceived 
as ineffective.
PIH27
PredICtIng medICatIOn adHerenCe and HealtHCare COStS In a 
managed Care POPUlatIOn
Lee JS, Sun P, Conrad CM, Lew HC, Solow BK, Stockl KM
OptumRx, Irvine, CA, USA
Objectives: To develop and validate predictive models that identify members 
with higher risk of medication non-adherence and increased total healthcare 
cost over a 12-month period in a managed care setting. MethOds: The study 
included members insured under a commercial healthcare plan who filled ≥ 1 
prescription for any of seven targeted medication classes for common chronic 
diseases between October 2010 and May 2014. Pharmacy and medical claims dur-
ing the four months before and six months after the member’s first prescription 
for a targeted medication (index date) were used to generate 85 baseline member 
variables. These variables were tested for potential model inclusion to separately 
predict medication non-adherence (proportion of days covered < 80%) and total 
healthcare costs during the 12-month follow-up period. Total costs included phar-
macy and medical costs from outpatient, emergency room, and inpatient visits. 
Members were randomized 3:1 to the development or validation samples. The 
development sample was used to estimate and refine model parameters. The 
validation sample was used to evaluate the final model’s performance based on 
c-statistic and R-squared values. Medication non-adherence was predicted using 
a logistic model. Total healthcare cost was predicted via a generalized linear model 
with a log link function and gamma distribution. Results: Among the 70,502 and 
23,505 members included in the development and validation samples, respec-
tively, baseline prevalence of medication non-adherence ranged from 37% to 73%, 
depending on the medication class. Baseline adherence and cost were the most 
important predictors. Predictive performance improved when other variables, 
such as member demographics and comorbidities, were added to the baseline 
adherence only model (c-statistic increased from 0.81 to 0.89; p< 0.0001). The cost 
model’s R-squared value was 0.43. cOnclusiOns: The models demonstrated 
good predictive performance and could be used together to identify members 
with potential non-adherence to medications and greater healthcare costs for 
intensive clinical interventions.
PIH28
a revIeW Of tHe effeCtIveneSS Of vISUal medICatIOn tOOlS In 
BOOStIng PatIent adHerenCe and redUCIng HOSPItal admISSIOnS
Anifowoshe R
Mercer, Norcross, GA, USA
Objectives: Thirty-two million Americans use three or more medications daily. 
Approximately 75% of patients fail to adhere to physician prescribed treatment 
regimens. The economic impact of non-adherence is estimated to cost $100 billion 
annually. Evidence suggests that the elderly are one of the largest groups contribut-
ing to the economic burden associated with non-adherence. Studies support the 
development of visual focused tools to improve adherence among older persons. 
The aim of this study was to explore the use of visual adherence tools in the hos-
pital, clinic, and home settings to determine effectiveness in improving patient 
adherence and negating hospital readmissions. MethOds: Electronic databases 
such as PubMed and Google Scholar were searched from 2000 – 2014. Key words 
were “visual,” “adherence,” “elderly,” “readmissions,” and “visual adherence tool.” 
Studies were included if they were conducted outside of the U.S. since few U.S. 
studies examined visual adherence tools. A custom-designed table included year 
of publication, author, study design, intervention, findings, and sources. Results: 
A total of 24 articles and economic evaluations were retrieved. Older adults are the 
largest users of prescription medication. Whilst evidence suggests that visual medi-
cation adherence tools are useful, the tools are not being widely used in hospitals. 
This may be due to lack of knowledge about benefits. Exploration in psychology and 
marketing denotes that humans have a cognitive preference for picture-based, as 
opposed to text-based information. Reports have shown that pictorial aids expand 
recall, comprehension, and adherence. These instruments can also be particularly 
valuable for conveying dosage times, instructions on when to take medicine, as 
well as the importance of completing a course of therapy. Studies show that older 
persons prefer medication tools that focus on visual characteristics such as large 
print and simplified information. cOnclusiOns: Several studies focused on the 
clinic and home setting, but few were hospital based. Further research is warranted.
PIH29
aSSeSSment Of level Of medICatIOn adHerenCe In dIfferent nOn-
COmmUnICaBle CHrOnIC dISeaSeS PatIent In QUetta, PakIStan: dOSe 
dISeaSe COndItIOn PrOdUCeS any CHange
ul Haq N1, Shaheen H1, Iqbal Q1, Naseem A1, Razaq G1, Younis M1, Bashir S2
1University of Balochistan, Quetta, Pakistan, 2University of Sargodha, Sargodha, Pakistan
Objectives: This study aimed to assess the level of medication adherence among 
patients with different non-communicable chronic diseases in Quetta Baluchistan, 
Pakistan. MethOds: A cross sectional study was conducted in different non-com-
municable chronic diseases patient, visiting outpatient department in public/private 
hospitals and clinics of Quetta, Pakistan. Morisky Medication Adherence Scale (Urdu 
version) was used to collect the data. The descriptive statistics was used to present 
the demographic and disease related information. Inferential statistics was used 
to the evaluation relationship among study variables. All analyses were performed 
using SPSS 20.0. Results: A total of 505 patients with different non- chronic dis-
eases (Diabetes, Hypertension, Heart diseases, Asthma and others) were enrolled for 
the present study. The mean age of the patients was 44.9 years, majority 304 (60.2%) 
were females. There were 228, 134, 37, 32 and 74 patients for diabetes, hypertension, 
heart diseases, asthma and others respectively. There was significant statistical 
difference (p = 0.004) as present mean mediation adherence scores in different 
non-communicable chronic diseases condition (5.34, 5.05, 4.65, 4.69, 4.59 for diabe-
tes, hypertension, heart diseases, asthma and others respectively) cOnclusiOns: 
The present study concluded that different disease conditions did affect the level 
of medication adherence, efforts should be made to provide specified health edu-
cation to improve medication adherence in different disease condition for better 
therapeutic outcome.
PIH30
aSSeSSment Of medICatIOn adHerenCe amOng PatIentS WItH nOn-
COmmUnICaBle CHrOnIC dISeaSeS In QUetta BalUCHIStan, PakIStan
ul Haq N1, Shaheen H1, Iqbal Q1, Naseem A1, Razaq G1, Younis M1, Iqbal J2
1University of Balochistan, Quetta, Pakistan, 2University of Sargodha, Sargodha, Pakistan
Objectives: This study aimed to assess the level of medication adherence 
among patients with non-communicable chronic diseases in Quetta Baluchistan, 
Pakistan. MethOds: A cross sectional study was conducted among patients with 
non- chronic diseases, visiting outpatient department in public/private hospitals and 
clinics of Quetta city. Morisky Medication Adherence Scale (Urdu version) was used to 
collect the data. The descriptive statistics was used to present the demographic and 
disease related information. Inferential statistics was used to the evaluation relation-
ship among study variables. All analyses were performed using SPSS 20.0. Results: 
A total of 505 patients with non- chronic diseases (Diabetes, Hypertension, Heart 
diseases, Asthma and others) were enrolled for the present study. The mean age of 
the patients was 44.9 years, majority 304 (60.2%) were females. The proportions of 
diseases were; diabetes (45.1%) hypertension (26.5%) heart diseases (7.3%) asthma 
(6.3%) mainly and other (14.7%). A very small proportion of the patient 11.1% were 
having good medication adherence while 27.9% were having moderate adherence 
and 61.0% exhibited poor adherence. cOnclusiOns: The study concluded that level 
of medication adherence among patients with non- communicable chronic disease 
was very poor, efforts should be made to identify the factors associated with non-
adherence so that level of adherence should be improved to achieve better therapeutic 
outcome.
PIH31
deSCrIBIng medICatIOn adHerenCe aCrOSS a POPUlatIOn: tHe valUe Of 
COnSIderIng mUltIPle meaSUreS
Aguilar KM1, Hou Q2, Miller RM1
1Cerner, Culver City, CA, USA, 2Cerner, Kansas City, MO, USA
